Wegovy Vs. Foundayo Pill: Which Is Better For Weight Loss?

GLP-1 weight-loss medications have officially become one of the biggest conversations in healthcare, and the options keep multiplying. If the thought of giving yourself a weekly shot makes you cringe, there’s some good news: you now have oral options to consider, including the Wegovy pill and the newly approved Foundayo. Both are designed to be used alongside a reduced-calorie diet and increased physical activity to help adults lose excess weight and keep it off.

But with more choices comes the inevitable question: Which one is actually better?

RELATED CONTENT: Serena Williams Stuns With Dramatic 31-Pound Weight Loss After Turning To GLP-1 Medication—’It Isn’t A Shortcut’

For people who aren’t exactly fans of needles, the appeal of a daily pill is pretty obvious. Instead of reaching for an injection, you can take your medication by mouth. But Wegovy and Foundayo aren’t simply two versions of the same drug. They contain different active ingredients, work somewhat differently in the body, and have very different rules when it comes to taking them. Here’s what to know before you decide which one sounds like the better fit.

Wegovy: The Semaglutide Option

The Wegovy pill is manufactured by Novo Nordisk and contains semaglutide, the same active ingredient used in injectable Wegovy. Unlike Foundayo, the tablet has specific instructions for how and when you take it. It should be taken once a day in the morning on an empty stomach with up to four ounces of plain water. After taking it, you need to wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications.

“Semaglutide has the longest real-world track record of any [GLP-1 agent],” Tony Yang, DSc, MPH, professor in the Milken Institute School of Public Health in the Department of Health Policy and Management and associate dean for Health Policy and Population Science at George Washington University, told SELF during an interview published April 2. “Physicians have years of experience managing its side effects, drug interactions, and dosing nuances.”

The Wegovy pill works by mimicking GLP-1, a hormone involved in regulating appetite and food intake. In simple terms, it helps you feel fuller and can reduce hunger, which can make sticking with a reduced-calorie eating plan a little easier. Because oral semaglutide is a peptide-based medication, however, its absorption is more sensitive to how it is taken. The current FDA label says its absorption predominantly occurs in the stomach, with an estimated oral bioavailability of about 1% to 2%.

And yes, the timing rules are real. The Wegovy pill is designed to be part of your morning routine, but it does require that 30-minute buffer before breakfast, coffee, other drinks or your other morning medications. For some people, that’s no big deal. For others, it could feel like one more thing to remember before the day gets rolling.

Foundayo: The New Kid on the GLP-1 Block

Made by pharmaceutical giant Eli Lilly, Foundayo contains orforglipron and was approved by the FDA in April 2026. Like Wegovy, it is a GLP-1 receptor agonist prescribed alongside a reduced-calorie diet and increased physical activity for certain adults with obesity or overweight plus a weight-related medical condition. But here’s one of Foundayo’s biggest selling points: You can take it with or without food, at any time of day.

That means you don’t have to wake up, take your pill and then stare at the clock waiting for breakfast. You simply swallow the tablet whole and keep moving. There’s no required fasting window, although taking it around the same time every day may make it easier to turn the medication into a consistent habit.

Foundayo, aka Orforglipron, requires patients to start on a lower dose before increasing to higher doses of the medication. “Orforglipron mimics GLP-1, a hormone your gut naturally releases after eating—the one that tells your brain, ‘Okay, we’re done here,’” Dr. Yang says. “What makes it genuinely novel is its chemistry: It’s a small molecule, not a peptide,” he continues. “That distinction matters enormously.”

Peptide-based GLP-1s like semaglutide—again, the active ingredient in Wegovy—get broken down by stomach acid, which is why they’ve historically required injections or very strict fasting protocols in the pill form to survive digestion, Dr. Yang explains.“Orforglipron’s small molecule structure lets it pass through the gut intact regardless of what you’ve eaten or when,” Dr. Yang says. “No fasting window, no timing your coffee. You just take it.”

Absorption: This Is Where Things Get Interesting

One of the biggest differences between the two medications comes down to chemistry. Foundayo is a non-peptide, small-molecule GLP-1 receptor agonist, while Wegovy contains semaglutide, a peptide. That difference helps explain why the two pills behave differently once they enter your digestive system.

Foundayo’s small-molecule structure allows it to be taken without regard to meals. Wegovy, on the other hand, has more specific administration instructions because semaglutide’s absorption depends on the formulation and the way the tablet is taken. According to the FDA, it reaches maximum concentration about one hour after a dose.

Foundayo reaches peak concentration later, approximately four to eight hours after a dose, but that doesn’t mean it necessarily “starts working” more slowly. Peak blood concentration and the time it takes for a medication to produce its clinical effects are not the same thing. In other words, don’t look at those numbers as a stopwatch for when weight loss begins.

Foundayo also has substantially greater oral bioavailability than semaglutide in the Wegovy tablet formulation. Because orforglipron is a small molecule that is less vulnerable to degradation in the digestive tract, its absorption is much more efficient.

Which Is More Effective for Weight Loss: Foundayo or Wegovy?

This is where things get interesting, and where it’s important not to treat two separate clinical trials like they are one head-to-head showdown. There has not been a direct trial comparing Wegovy and Foundayo against each other, so saying one is definitively “better” based solely on their separate studies would be misleading.

According to RO, in the phase 3 ATTAIN-1 trial, people with obesity who received the highest studied dose of orforglipron lost an average of 11.2% of their body weight after 72 weeks, compared with 2.1% with placebo.

In the OASIS 4 trial, adults with overweight or obesity who took 25 mg of oral semaglutide lost an estimated average of 13.6% of their body weight by week 64, compared with 2.2% with placebo.

So, on paper, the oral semaglutide study produced a larger average weight loss than the highest-dose orforglipron group. But because these were different studies involving different populations, designs and treatment periods, those percentages should not be interpreted as proof that the Wegovy pill will outperform Foundayo in every individual.

And there’s another important point: both medications can cause gastrointestinal side effects. Foundayo’s most common adverse reactions include nausea, constipation, diarrhea, vomiting, abdominal pain and other digestive symptoms. The Wegovy tablet also carries the gastrointestinal side-effect profile associated with semaglutide.

Foundayo vs. Wegovy: Doses and Dosage Schedules

Both Foundayo and Wegovy are taken once daily, but their dosage schedules and strengths are different. Foundayo is available in six tablet strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg. Treatment starts at 0.8 mg once daily, with increases occurring after at least 30 days at each dose, depending on response and tolerability. The maximum dose is 17.2 mg once daily.

Wegovy is available in 1.5 mg, 4 mg, 9 mg and 25 mg tablets, with gradual dose escalation before reaching the recommended maintenance dose of 25 mg daily for the tablet formulation.

Both medications use a gradual titration approach, meaning you don’t start at the highest dose on day one. Instead, the dosage is increased over time to give your body an opportunity to adjust and to help manage side effects. With Foundayo, the FDA labeling specifies increases after at least 30 days at each dose level, while Wegovy also follows a step-up dosing schedule. Your healthcare provider may adjust the pace based on how you respond to treatment and how well you tolerate the medication, RO noted.

So, Which One Should You Choose?

The short answer? There isn’t one winner for everyone.

If your biggest priority is taking a pill without worrying about food or fasting, Foundayo has a major convenience advantage. If you’re comfortable following the morning fasting instructions and want a medication with a longer track record of real-world use, Wegovy may be appealing. And when it comes to the clinical-trial weight-loss numbers, both have demonstrated meaningful results, but their studies were not designed as a direct head-to-head competition.

There are also important safety considerations with both medications. For example, both Wegovy and Foundayo carry boxed warnings related to thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or by people with MEN 2. Foundayo also should not be taken with another GLP-1 receptor agonist.

Ultimately, the “best” medication isn’t necessarily the one with the biggest percentage in a clinical trial. It’s the one that makes sense for your health history, other medications, lifestyle, goals and ability to stick with the treatment plan. That’s a conversation worth having with your healthcare provider before starting or switching medications.

RELATED CONTENT: Nature’s Ozempic’ Or Just Another Diet Fad? Why Thousands Of Women Are Drinking Gelatin To Lose Weight—And What Doctors Want You To Know